Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Recent advances in managing hepatitis D.

F1000Research

Yurdaydin C.
PMID: 28928961
F1000Res. 2017 Aug 30;6:1596. doi: 10.12688/f1000research.11796.1. eCollection 2017.

Hepatitis D virus (HDV) infection leads to the most severe form of chronic viral hepatitis and requires the attention of a liver specialist. In this review, I will recapitulate recent advances in the management of HDV, present background information...

Cite
Yurdaydin C. Recent advances in managing hepatitis D. F1000Res. 2017;6:1596doi: 10.12688/f1000research.11796.1.
Yurdaydin, C. (2017). Recent advances in managing hepatitis D. F1000Research, 61596. https://doi.org/10.12688/f1000research.11796.1
Yurdaydin, Cihan. "Recent advances in managing hepatitis D." F1000Research vol. 6 (2017): 1596. doi: https://doi.org/10.12688/f1000research.11796.1
Yurdaydin C. Recent advances in managing hepatitis D. F1000Res. 2017 Aug 30;6:1596. doi: 10.12688/f1000research.11796.1. eCollection 2017. PMID: 28928961; PMCID: PMC5580405.
Copy Download .nbib Format: NLM
Before Saying Goodbye Some Recollection and Some Humble Suggestions.

Journal of clinical gastroenterology

Yurdaydin C.
PMID: 34999645
J Clin Gastroenterol. 2022 Jan 10; doi: 10.1097/MCG.0000000000001658. Epub 2022 Jan 10.

No abstract available.

Cite
Yurdaydin C. Before Saying Goodbye Some Recollection and Some Humble Suggestions. J Clin Gastroenterol. 2022;doi: 10.1097/MCG.0000000000001658.
Yurdaydin, C. (2022). Before Saying Goodbye Some Recollection and Some Humble Suggestions. Journal of clinical gastroenterology, . https://doi.org/10.1097/MCG.0000000000001658
Yurdaydin, Cihan. "Before Saying Goodbye Some Recollection and Some Humble Suggestions." Journal of clinical gastroenterology vol. (2022). doi: https://doi.org/10.1097/MCG.0000000000001658
Yurdaydin C. Before Saying Goodbye Some Recollection and Some Humble Suggestions. J Clin Gastroenterol. 2022 Jan 10; doi: 10.1097/MCG.0000000000001658. Epub 2022 Jan 10. PMID: 34999645.
Copy Download .nbib Format: NLM
The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?.

Archives of public health = Archives belges de sante publique

Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M.
PMID: 34663473
Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2.

BACKGROUND: Co-infection between hepatitis B virus (HBV) and hepatitis delta virus (HDV) causes the severest chronic hepatitis and is associated with a high risk of cirrhosis and hepatocellular carcinoma (HCC). The Global Health Sector Strategy on Viral Hepatitis called...

Cite
Hayashi T, Takeshita Y, Hutin YJ, et al. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Arch Public Health. 2021;79(1):180doi: 10.1186/s13690-021-00693-2.
Hayashi, T., Takeshita, Y., Hutin, Y. J., Harmanci, H., Easterbrook, P., Hess, S., van Holten, J., Oru, E. O., Kaneko, S., Yurdaydin, C., & Bulterys, M. (2021). The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Archives of public health = Archives belges de sante publique, 79(1), 180. https://doi.org/10.1186/s13690-021-00693-2
Hayashi, Tomoyuki, et al. "The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?." Archives of public health = Archives belges de sante publique vol. 79,1 (2021): 180. doi: https://doi.org/10.1186/s13690-021-00693-2
Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2. PMID: 34663473; PMCID: PMC8525025.
Copy Download .nbib Format: NLM
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B.

JHEP reports : innovation in hepatology

Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P.
PMID: 34041470
JHEP Rep. 2021 Apr 20;3(3):100290. doi: 10.1016/j.jhepr.2021.100290. eCollection 2021 Jun.

BACKGROUND & AIMS: Recently, several risk scores for prediction of hepatocellular carcinoma (HCC) were developed in cohorts of treated Asian patients with chronic hepatitis B (CHB), but they have not been assessed in non-Asian patients. We evaluated the predictability...

Cite
Papatheodoridis GV, Dalekos GN, Idilman R, et al. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep. 2021;3(3):100290doi: 10.1016/j.jhepr.2021.100290.
Papatheodoridis, G. V., Dalekos, G. N., Idilman, R., Sypsa, V., Van Boemmel, F., Buti, M., Calleja, J. L., Goulis, J., Manolakopoulos, S., Loglio, A., Papatheodoridi, M., Gatselis, N., Veelken, R., Lopez-Gomez, M., Hansen, B. E., Savvidou, S., Kourikou, A., Vlachogiannakos, J., Galanis, K., Yurdaydin, C., Esteban, R., Janssen, H. L. A., Berg, T., & Lampertico, P. (2021). Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP reports : innovation in hepatology, 3(3), 100290. https://doi.org/10.1016/j.jhepr.2021.100290
Papatheodoridis, George V, et al. "Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B." JHEP reports : innovation in hepatology vol. 3,3 (2021): 100290. doi: https://doi.org/10.1016/j.jhepr.2021.100290
Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep. 2021 Apr 20;3(3):100290. doi: 10.1016/j.jhepr.2021.100290. eCollection 2021 Jun. PMID: 34041470; PMCID: PMC8144729.
Copy Download .nbib Format: NLM
Developing New Therapies for Delta Hepatitis: The Race Is On.

Hepatology communications

Gençdal G, Yurdaydin C.
PMID: 33860114
Hepatol Commun. 2021 Apr 09;5(4):556-558. doi: 10.1002/hep4.1685. eCollection 2021 Apr.

No abstract available.

Cite
Gençdal G, Yurdaydin C. Developing New Therapies for Delta Hepatitis: The Race Is On. Hepatol Commun. 2021;5(4):556-558doi: 10.1002/hep4.1685.
Gençdal, G., & Yurdaydin, C. (2021). Developing New Therapies for Delta Hepatitis: The Race Is On. Hepatology communications, 5(4), 556-558. https://doi.org/10.1002/hep4.1685
Gençdal, Genco, and Yurdaydin, Cihan. "Developing New Therapies for Delta Hepatitis: The Race Is On." Hepatology communications vol. 5,4 (2021): 556-558. doi: https://doi.org/10.1002/hep4.1685
Gençdal G, Yurdaydin C. Developing New Therapies for Delta Hepatitis: The Race Is On. Hepatol Commun. 2021 Apr 09;5(4):556-558. doi: 10.1002/hep4.1685. eCollection 2021 Apr. PMID: 33860114; PMCID: PMC8034575.
Copy Download .nbib Format: NLM
Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us.

Hepatology (Baltimore, Md.)

Keskin O, Yurdaydin C.
PMID: 32767786
Hepatology. 2021 Aug;74(2):1127. doi: 10.1002/hep.31501.

No abstract available.

Cite
Keskin O, Yurdaydin C. Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us. Hepatology. 2021;74(2):1127doi: 10.1002/hep.31501.
Keskin, O., & Yurdaydin, C. (2021). Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us. Hepatology (Baltimore, Md.), 74(2), 1127. https://doi.org/10.1002/hep.31501
Keskin, Onur, and Yurdaydin, Cihan. "Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us." Hepatology (Baltimore, Md.) vol. 74,2 (2021): 1127. doi: https://doi.org/10.1002/hep.31501
Keskin O, Yurdaydin C. Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us. Hepatology. 2021 Aug;74(2):1127. doi: 10.1002/hep.31501. PMID: 32767786.
Copy Download .nbib Format: NLM
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.

Hepatology communications

Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B.
PMID: 34561972
Hepatol Commun. 2021 Sep 24; doi: 10.1002/hep4.1821. Epub 2021 Sep 24.

Standard treatment of hepatitis delta virus (HDV) infection remains pegylated-interferon alfa (peg-IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core-related antigen (HBcrAg) is linked to intrahepatic covalently closed...

Cite
Sandmann L, Yurdaydin C, Deterding K, et al. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun. 2021;doi: 10.1002/hep4.1821.
Sandmann, L., Yurdaydin, C., Deterding, K., Heidrich, B., Hardtke, S., Lehmann, P., Bremer, B., Manns, M. P., Cornberg, M., Wedemeyer, H., Maasoumy, B. (2021). HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatology communications, . https://doi.org/10.1002/hep4.1821
Sandmann, Lisa, et al. "HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1821
Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P, Bremer B, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatol Commun. 2021 Sep 24; doi: 10.1002/hep4.1821. Epub 2021 Sep 24. PMID: 34561972.
Copy Download .nbib Format: NLM
Hepatitis d.

Current treatment options in gastroenterology

Koytak ES, Yurdaydin C, Glenn JS.
PMID: 18221606
Curr Treat Options Gastroenterol. 2007 Dec;10(6):456-63. doi: 10.1007/s11938-007-0045-8.

The hepatitis delta virus (HDV) is a defective RNA virus that requires the help of hepatitis B virus (HBV) for virion assembly and penetration into hepatocytes. Thus, it can only cause disease in individuals who carry HBV. HDV infection...

Cite
Koytak ES, Yurdaydin C, Glenn JS. Hepatitis d. Curr Treat Options Gastroenterol. 2007;10(6):456-63doi: 10.1007/s11938-007-0045-8.
Koytak, E. S., Yurdaydin, C., & Glenn, J. S. (2007). Hepatitis d. Current treatment options in gastroenterology, 10(6), 456-63. https://doi.org/10.1007/s11938-007-0045-8
Koytak, Elif S, et al. "Hepatitis d." Current treatment options in gastroenterology vol. 10,6 (2007): 456-63. doi: https://doi.org/10.1007/s11938-007-0045-8
Koytak ES, Yurdaydin C, Glenn JS. Hepatitis d. Curr Treat Options Gastroenterol. 2007 Dec;10(6):456-63. doi: 10.1007/s11938-007-0045-8. PMID: 18221606.
Copy Download .nbib Format: NLM
A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.

Hepatology (Baltimore, Md.)

Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, Kalkan Ç, Karatayli E, Karatayli S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS.
PMID: 34860418
Hepatology. 2021 Dec 03; doi: 10.1002/hep.32259. Epub 2021 Dec 03.

BACKGROUND AND AIMS: Proof-of-concept studies demonstrated lonafarnib (LNF), a first-in-class oral prenylation inhibitor, efficacy in patients infected with HDV. The lonafarnib with ritonavir for HDV-2 (LOWR-2) study's aim was to identify optimal combination regimens of LNF + ritonavir (RTV)...

Cite
Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2021;doi: 10.1002/hep.32259.
Yurdaydin, C., Keskin, O., Yurdcu, E., Çalişkan, A., Önem, S., Karakaya, F., Kalkan, �. �., Karatayli, E., Karatayli, S., Choong, I., Apelian, D., Koh, C., Heller, T., Idilman, R., Bozdayi, A. M., & Glenn, J. S. (2021). A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32259
Yurdaydin, Cihan, et al. "A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32259
Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, Kalkan Ç, Karatayli E, Karatayli S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2021 Dec 03; doi: 10.1002/hep.32259. Epub 2021 Dec 03. PMID: 34860418.
Copy Download .nbib Format: NLM
A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection.

Viruses

Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S.
PMID: 34960640
Viruses. 2021 Nov 26;13(12). doi: 10.3390/v13122371.

Hepatitis Delta virus (HDV) is a satellite of the Hepatitis B virus (HBV) and causes severe liver disease. The estimated prevalence of 15-20 million infected people worldwide may be underestimated as international diagnostic guidelines are not routinely followed. Possible...

Cite
Lempp FA, Roggenbach I, Nkongolo S, et al. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses. 2021;13(12)doi: 10.3390/v13122371.
Lempp, F. A., Roggenbach, I., Nkongolo, S., Sakin, V., Schlund, F., Schnitzler, P., Wedemeyer, H., Le Gal, F., Gordien, E., Yurdaydin, C., & Urban, S. (2021). A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses, 13(12), . https://doi.org/10.3390/v13122371
Lempp, Florian A, et al. "A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122371
Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses. 2021 Nov 26;13(12). doi: 10.3390/v13122371. PMID: 34960640; PMCID: PMC8703323.
Copy Download .nbib Format: NLM
World Gastroenterology Organisation Global Guidelines: Diet and the Gut.

Journal of clinical gastroenterology

Makharia G, Gibson PR, Bai JC, Karakan T, Lee YY, Collins L, Muir J, Oruc N, Quigley E, Sanders DS, Tuck C, Yurdaydin C, Le Mair A.
PMID: 34860201
J Clin Gastroenterol. 2022 Jan 01;56(1):1-15. doi: 10.1097/MCG.0000000000001588.

No abstract available.

Cite
Makharia G, Gibson PR, Bai JC, et al. World Gastroenterology Organisation Global Guidelines: Diet and the Gut. J Clin Gastroenterol. 2022;56(1):1-15doi: 10.1097/MCG.0000000000001588.
Makharia, G., Gibson, P. R., Bai, J. C., Karakan, T., Lee, Y. Y., Collins, L., Muir, J., Oruc, N., Quigley, E., Sanders, D. S., Tuck, C., Yurdaydin, C., & Le Mair, A. (2022). World Gastroenterology Organisation Global Guidelines: Diet and the Gut. Journal of clinical gastroenterology, 56(1), 1-15. https://doi.org/10.1097/MCG.0000000000001588
Makharia, Govind, et al. "World Gastroenterology Organisation Global Guidelines: Diet and the Gut." Journal of clinical gastroenterology vol. 56,1 (2022): 1-15. doi: https://doi.org/10.1097/MCG.0000000000001588
Makharia G, Gibson PR, Bai JC, Karakan T, Lee YY, Collins L, Muir J, Oruc N, Quigley E, Sanders DS, Tuck C, Yurdaydin C, Le Mair A. World Gastroenterology Organisation Global Guidelines: Diet and the Gut. J Clin Gastroenterol. 2022 Jan 01;56(1):1-15. doi: 10.1097/MCG.0000000000001588. PMID: 34860201.
Copy Download .nbib Format: NLM
A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection.

Viruses

Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S.
PMID: 34960640
Viruses. 2021 Nov 26;13(12). doi: 10.3390/v13122371.

Hepatitis Delta virus (HDV) is a satellite of the Hepatitis B virus (HBV) and causes severe liver disease. The estimated prevalence of 15-20 million infected people worldwide may be underestimated as international diagnostic guidelines are not routinely followed. Possible...

Cite
Lempp FA, Roggenbach I, Nkongolo S, et al. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses. 2021;13(12)doi: 10.3390/v13122371.
Lempp, F. A., Roggenbach, I., Nkongolo, S., Sakin, V., Schlund, F., Schnitzler, P., Wedemeyer, H., Le Gal, F., Gordien, E., Yurdaydin, C., & Urban, S. (2021). A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses, 13(12), . https://doi.org/10.3390/v13122371
Lempp, Florian A, et al. "A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122371
Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses. 2021 Nov 26;13(12). doi: 10.3390/v13122371. PMID: 34960640.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries